Author's response to reviews

Title: Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Authors:

Meriem Hasmim (Meriem.Hasmim@igr.fr)
Cecile Badoual (cecile.badoual@egp.aphp.fr)
Philippe Vielh (Philippe.Vielh@igr.fr)
Françoise Drusch (Francoise.Drusch@igr.fr)
Virginie Marty (Virginie.Marty@igr.fr)
Agnes Laplanche (Agnes.Laplanche@igr.fr)
Mariana de Oliveira Diniz (modiniz@usp.br)
Hélène Roussel (helene.roussel@egp.aphp.fr)
Eléonore De Guillebon (eleonore04@gmail.com)
Stéphane Oudard (stephane.oudard@egp.aphp.fr)
Stéphane Hans (stephane.hans@egp.aphp.fr)
Eric Tartour (saeric.tartour@egp.aphp.fr)
Salem Chouaib (salem.chouaib@igr.fr)

Version: 5 Date: 27 November 2013

Author's response to reviews: see over
Manuscript **MS: 1677578026990062**, “Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.”

Dear Executive Editor,

We are very pleased with your acceptance of our work. Although we agree with Reviewer 1 that larger cohorts of more than 100 patients may provide more significant data, we believe that our clear and concise conclusions are based on an immunohistochemical staining on 83 patients. This is a relatively small cohort but of acceptable size (see Badoual C Clin Cancer Res 2006; Badoual Canc Res 2013).

Thank you for your time and effort, I look forward to hearing your decision.

Sincerely yours,

S Chouaib

Corresponding author, U753 INSERM, Gustave Roussy, 114 rue Edouard Vaillant 94805 Villejuif cedex, France. Phone: +33142114547, Fax: +33142115288, Email: chouaib@igr.fr

Enclosed:

*A point-by-point reply to Reviewer’s comments.

*A Word file of the manuscript.*